You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 81-93 of 93 results found

Single domain CD4, HIV-1 Antibodies, and Fusion Proteins for treatment of HIV

Researchers at the National Cancer Institute (NCI) have developed single domain human CD4 proteins to inhibit HIV-1 entry and improved human domain antibodies against HIV-1. Fusion proteins comprising the single domain CD4 and HIV-1 antibody can be used to effectively neutralize HIV-1 in vitro. Researchers seek licensing for development of these antibody-based therapeutics for the treatment of HIV-1.
  • Therapeutics

Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL) of cancer patients. This method generates accurate scoring of single T cells from tumors, as well as facilitates identification and reconstruction of unknown TCRs for immunotherapy.
  • Therapeutics

Software for Accurate Segmentation of Cell Nuclei in Breast Tissue

The Office of the Director, National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research (using the Cooperative Research and Development Agreement (CRADA) or Material Transfer Agreement (MTA) to further develop, evaluate, or commercialize the software for accurate segmentation of cell nuclei and FISH signals in tissue sections. Collaborators working in the field of quantitative and automated pathology may be interested.
  • Software

T cell tuning molecules that modify the immune response to cancer cells

Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seek partners to collaborate on in vitro studies to validate these potential immunomodulators and to conduct in vivo studies in a murine cancer model to determine the effects of ligands (e.g., antibodies) to the proteins on the immune response to cancer cells. Preference will be given to responses received by March 31, 2016.
  • Therapeutics

Anti-CD133 Monoclonal Antibodies as Cancer Therapeutics

Researchers at NCI developed a rabbit monoclonal antibody that recognizes the marker for CD133 and is useful in pharmacodynamic testing to inform targeted anti-cancer chemotherapy development and clinical monitoring. CD133 is a cell surface glycoprotein used as a marker and expressed in stem cells such as hematopoietic stem cells, endothelial progenitor cells and neural stem cells. The NCI seeks collaborative co-development or licensing partners for this technology.
  • Diagnostics
  • Therapeutics

Anti-Py1235-Met Immunological Binding Reagent as Cancer Diagnostic

This technology consists of highly specific rabbit monoclonal antibodies reactive with phosphorylated tyrosine located at amino acid 1235 in the human MET sequence. Binding to this pYl235 residue is independent of the phosphorylation of other tyrosines in the vicinity (1230 and 1234), does not cross-react with these nearby phosphotyrosine residues, and does not occur when Y1235 is unphosphorylated. Researchers at the NCI seek licensing and/or co-development research collaborations  to commercialize and develop a companion diagnostic for selective MET inhibitors.
  • Diagnostics

New T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors

Researchers at the National Cancer Institute’s Experimental Transplantation and Immunology Branch (NCI ETIB) developed a T Cell receptor that specifically targets the Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) 52-60 epitope that is highly expressed by several common and aggressive epithelial tumor types.
  • Therapeutics

Synthetic Bacterial Nanoparticles as Drug and Vaccine Delivery Vehicles

Engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants. Researchers at the National Cancer Institute’s Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions. NCI seeks partners to license and/or co-develop this technology toward commercialization.
  • Therapeutics
  • Vaccines
  • Devices

Pages